Short Interest in Sysmex Corporation ADR (OTCMKTS:SSMXY) Increases By 111.6%

Sysmex Corporation ADR (OTCMKTS:SSMXY) saw a significant increase in short interest in March. As of March 13th, there was short interest totaling 87,678 shares, an increase of 111.6% from the February 26th total of 41,438 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 591,040 shares, the days-to-cover ratio is currently 0.1 days.

Sysmex Price Performance

OTCMKTS:SSMXY opened at $8.46 on Thursday. The firm has a market capitalization of $5.33 billion, a price-to-earnings ratio of 17.63 and a beta of 1.14. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44. The business has a 50 day simple moving average of $9.17 and a 200-day simple moving average of $10.30. Sysmex has a 1 year low of $8.15 and a 1 year high of $19.65.

Sysmex (OTCMKTS:SSMXY) last released its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. Sysmex had a return on equity of 9.27% and a net margin of 8.86%.The firm had revenue of $837.32 million for the quarter, compared to the consensus estimate of $819.99 million. Equities analysts forecast that Sysmex will post 0.57 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Citigroup cut shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.